Next Article in Journal
Transcriptome Analysis of Core Dinoflagellates Reveals a Universal Bias towards “GC” Rich Codons
Previous Article in Journal
Peptides, Peptidomimetics, and Polypeptides from Marine Sources: A Wealth of Natural Sources for Pharmaceutical Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Marine Drugs
Volume 15
Issue 5
10.3390/md15050126
marinedrugs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review Study on Macrolides Isolated from Cyanobacteria

by
Mengchuan Wang
1,
Jinrong Zhang
1,*,
Shan He
1 and
Xiaojun Yan
2
1
School of Marine Sciences, Laboratory of Marine Natural Products, Ningbo University, Ningbo 315211, China
2
Key Laboratory of Applied Marine Biotechnology of Ministry of Education, Ningbo University, Ningbo 315211, China
*
Author to whom correspondence should be addressed.
Mar. Drugs 2017, 15(5), 126; https://doi.org/10.3390/md15050126
Submission received: 27 January 2017 / Revised: 21 April 2017 / Accepted: 24 April 2017 / Published: 26 April 2017
Browse Figures
Versions Notes

Abstract

:
Cyanobacteria are rich sources of structurally-diverse molecules with promising pharmacological activities. Marine cyanobacteria have been proven to be true producers of some significant bioactive metabolites from marine invertebrates. Macrolides are a class of bioactive compounds isolated from marine organisms, including marine microorganisms in particular. The structural characteristics of macrolides from cyanobacteria mainly manifest in the diversity of carbon skeletons, complexes of chlorinated thiazole-containing molecules and complex spatial configuration. In the present work, we systematically reviewed the structures and pharmacological activities of macrolides from cyanobacteria. Our data would help establish an effective support system for the discovery and development of cyanobacterium-derived macrolides.

1. Introduction

Cyanobacteria, also known as blue-green algae, including cyanobacteria from terrestrial, freshwater and marine ecosystems, are a group of ancient photosynthetic prokaryotes. As defensive chemicals, structurally-diverse secondary metabolites from cyanobacteria have been proven to greatly contribute to successful survival and reproduction of cyanobacteria in changing, complex and diverse environments during the long-lasting evolutionary process [1]. At present, hundreds of compounds with important bioactivities have been isolated from terrestrial or marine cyanobacteria [2]. Macrolides are a class of important bioactive compounds, which are commonly found in marine organisms, including cyanobacteria [3]. Some marine macrolides are promising candidates for future applications in medicine. For example, bryostatin-1 shows potent antitumor activity in phase I cancer clinical trials [4]. Macrolide antibiotics, such as erythromycin and polyene macrolides, have been employed for widespread application of severe bacterial infections [5]. Structurally-diverse macrolides from cyanobacteria often contain unique and unusual substituents, including chlorinated residues, thiazole residues [6] or pyran residues [7]. Macrolides usually exhibit potent antitumor or antibacterial activities [8]. In addition, cyanobacteria have great potentials as sustainable sources for production of bioactive macrolides because of their rapid growth, genetic tractability and cultivable property [2]. Although cyanobacteria possess cultivable properties similar to those of microorganisms, cyanobacteria have attracted far less attention than microorganisms.
In the present review paper, we systematically summarized the structures and bioactivities of macrolides isolated from cyanobacteria, and over 50 references were cited. Up to the end of 2016, a total of 64 macrolide compounds have been isolated from cyanobacteria, including 49 macrolides from marine cyanobacteria and 15 macrolides from terrestrial cyanobacteria, most of which are mainly from Lyngbya, Scytonema and Oscillatoria. It has been reported that most of these cyanobacterium-derived macrolides possess several noticeable bioactivities, including antitumor, antibacterial, antimalarial and toxicity to animals. This review summarizes new macrolides derived from cyanobacteria, providing useful information in the further discovery of novel cyanobacterial macrolides.

2. Anti-Neoplastic Property of Cyanobacterium-Derived Macrolides on Different Cell Lines

Nitrogen mustard has been used in the treatment of lymphoma cancer since 1940s, and more than 100 anti-cancer drugs are widely used in the world. Until now, natural products have largely contributed to cancer therapy and become an indispensable source for the development of innovative anti-cancer drugs [9]. Most macrolides from cyanobacteria display significant cytotoxicity to cancer cells. Cyanobacteria of the genera Symploca, Lyngbya, Scytonema and Oscillatoria are important sources of anti-cancer macrolides. Cyanobacterium-derived macrolides reported to have anti-neoplastic effects on different cell lines are given in Figure 1 and Table 1.
A series of cytotoxic marine cyanobacterial metabolites, named lyngbyabellins (1–11) possessing thiazole residues and chlorine substituents, have been isolated from the cyanobacterial genus Lyngbya (Figure 2). Isolated from the marine cyanobacterium Lyngbya majuscula collected from Guam, lyngbyabellin A (1) exhibits potent in vitro cytotoxicity against human carcinoma of nasopharynx Cell (KB cells) and LoVo cells with IC50 values of 0.03 and 0.50 µg/mL, respectively [6]. The analog of lyngbyabellin A (1), lyngbyabellin B (2), was isolated from the same strain of Lyngbya majuscula. Compared with lyngbyabellin A (1), lyngbyabellin B (2) is slightly less cytotoxic to KB and LoVo cells with IC50 values of 0.10 and 0.83 µg/mL, respectively [10]. Five analogs of lyngbyabellin A (1), including lyngbyabellins E-I (3–7), are produced from the same strain of Lyngbya majuscula harvested in Papua New Guinea. To the best of our knowledge, lyngbyabellins E-I (3–7) have potent in vitro cytotoxicity against human lung tumor (NCI-H460) and mouse neuroblastoma (neuro-2a) cells. Lyngbyabellin E (3) and lyngbyabellin H (6) display significant cytotoxicity to NCI-H460 (LC50 values of 0.4 and 0.2 µM, respectively) and neuro-2a cells (LC50 values of 1.2 and 1.4 µM, respectively). Lyngbyabellins F-G (4–5) and lyngbyabellin I (7) are slightly less cytotoxic to NCI-H460 (LC50 values of 1.0, 2.2 and 1.0 µM, respectively) and neuro-2a cells (LC50 values of 1.8, 4.8 and 0.7 µM, respectively) [11]. The marine cyanobacterium Moorea bouillonii (formerly Lyngbya bouillonii) collected from Palmyra Atoll affords four analogs of lyngbyabellin A (1), lyngbyabellins K (8), L (9), N (10) and 7-epi-lyngbyabellin L (11). Lyngbyabellin N (10) shows variable cytotoxicity to H-460 human lung carcinoma (IC50 = 0.0048–1.8 μM) and potent in vitro cytotoxicity against the HCT116 colon cancer cell line (IC50 = 40.9 ± 3.3 nM). This result could perhaps be explained by the solubility problem of lyngbyabellin N (10). The nitrogen-containing side chain (leucine statine residue) of lyngbyabellin N (11) may be the basic structural feature for its cytotoxic activity [12].
Several 16-membered glycoside macrolides, termed lyngbyalosides, are produced from various species of the cyanobacterial genus Lyngbya (Figure 3). The marine Lyngbya bouillonii, collected from Laing Island, afford lyngbyaloside (12) [8]. Lyngbyaloside B (13), isolated from marine cyanobacterium Lyngbya sp., which was collected from Palaua, shows weak cytotoxicity against KB cells and LoVo cells with IC50 values of 4.3 and 15 µM, respectively [13]. The total synthesis of lyngbyaloside B (13) has been reported by Fuwa et al. [33]. Three analogs of lyngbyaloside (12), including 2-epi-lyngbyaloside (14), 18E-lyngbyaloside C (15) and 18Z-lyngbyaloside C (16), were isolated from the marine cyanobacterium Lyngbya bouillonii, collected from Apra Harbor, Guam. Cytotoxicity assays revealed that these macrolides possess weak to moderate cytotoxicity against the human colorectal adenocarcinoma cell line HT29 and HeLa cervical carcinoma cells. 18E-lyngbyaloside C (15) is more cytotoxic toward HT29 colorectal adenocarcinoma and HeLa cervical carcinoma cells (IC50 values of 13 and 9.3 µM, respectively) than 2-epi-lyngbyaloside (14) (IC50 values of 38 and 33 µM, respectively). 18E-Lyngbyaloside C (15) is approximately five-fold more cytotoxic than 18Z-lyngbyaloside C (16) (IC50 values of >100 µM and 53 µM, respectively) [14]. The total synthesis of lyngbyaloside C has also been accomplished [34].
Another distinct class of 18-membered ring glycoside macrolides has been isolated from the cyanobacterial genus Lyngbya (Figure 4). Biselyngbyaside (17) was discovered through a bioassay-guided screening for cytotoxic compounds from cyanobacterium Lyngbya sp. collected from Okinawa Prefecture, Japan. Biselyngbyaside (17) shows a broad spectrum of cytotoxicity against human solid tumor cell lines, especially for HeLa S3 cells with an IC50 value of 0.1 μg/mL [15], and its total synthesis was completed [35]. Extensive efforts toward finding cytotoxic natural products have resulted in the isolation of three analogs of biselyngbyaside (17), named biselyngbyasides B–D (18–20), from the marine cyanobacterium Lyngbya sp. Biselyngbyaside B (18) displays significant cytotoxicity against HeLa S3 and HL60 cells (IC50 values of 3.5 and 0.82 µM, respectively, using thapsigargin as a positive control drug). In addition, biselyngbyasides B-D (18–20) induced apoptosis of cancer cells by inhibiting calcium influx into the endoplasmic reticulum and increasing the concentration of intracellular calcium [16]. Two analogs of biselyngbyaside (17), biselyngbyasides E (21) and F (22), were isolated from the marine cyanobacterium Lyngbya sp. collected from Ishigaki Island, Japan. In vitro cell cytotoxicity assays showed that biselyngbyaside E (21) has higher cytotoxicity against HeLa and HL60 cells (IC50 values of 0.19 and 0.071 µM, respectively) than biselyngbyaside F (22) (IC50 values of 3.1 and 0.66 µM, respectively). Based on the trisubstituted olefin geometry, the presence and absence of the sugar moiety are crucial for the biological activities [17].
Like a cytotoxic biselyngbyaside-related macrolide, biselyngbyolide A (23) was isolated from the marine cyanobacterium Lyngbya sp. harvested from Tokunoshima Island, Japan. Biselyngbyolide A (23) shows strong cytotoxicity against HeLa S3 cells and HL60 cells with IC50 values of 0.22 and 0.027 µM, respectively [18]. Biselyngbyolide B (24) was also isolated from the same strain of Lyngbya sp. and displays significant inhibitory effects on growth of HeLa S3 cells and HL60 cells (IC50 values of 0.028 and 0.0027 µM, respectively, using thapsigargin as a positive control drug). Moreover, biselyngbyolide B (24) has 3–100-fold more potent apoptosis-inducing activity than biselyngbyaside (17) [16,19].
A novel 36-membered macrolactone, caylobolide A (25), was isolated from Bahamian cyanobacterium Lyngbya majuscula, which contains an unprecedented repeating unit, an adjoining pentad of 1,5-diols and a 1,3,5-triol (Figure 5). In vitro cytotoxicity assay showed that caylobolide A (25) possesses potent cytotoxicity against human colon tumor cells HCT-116 with an IC50 value of 9.9 µM [20], and its total synthesis has been accomplished [36]. Caylobolide B (26) was isolated from the marine cyanobacterium Phormidium spp. collected from Key West, Florida, and it exhibits strong cytotoxicity against HT29 colorectal adenocarcinoma (IC50 value of 4.5 µM) and HeLa cervical carcinoma cells (IC50 value of 12.2 µM) [21].
Swinholide A (27), originally isolated from the marine sponge Theonella swinhoei, was isolated from the marine cyanobacterium cf. Symploca sp. collected from Fiji and was found to strongly inhibit the growth of several tumor cell lines with IC50 values ranging from 0.37 nM to 1.0 μM [22]. Two swinholide-based glycosylated macrolides, named ankaraholides A,B (28,29), were isolated from two field collections of marine cyanobacteria (Figure 6). Ankaraholide A (28) exhibits strong antiproliferative activity against NCI-H460, Neuro-2a and MDA-MB-435 cell lines with IC50 values of 119, 262 and 8.9 nM, respectively. Ankaraholide A (28) inhibits proliferation of A-10 cells by inducing complete loss of the filamentous (F)-actin during the cell extending process when the concentration of ankaraholide A (28) reaches 30 nM [22].
A family of potent cytotoxic natural products, scytophycins A–E (30–34), was isolated from the terrestrial cyanobacterium Scytonema pseudohofmanni [37]. Scytophycins A (30) and B (31) display significant cytotoxicity against KB cells (IC50 value of 1 ng/mL), while scytophycins C-E (32–34) are less cytotoxic to KB cells (IC50 values ranging from 10 to 100 ng/mL) than scytophycin A (30) [23]. Total synthesis of scytophycin C (32) has been completed [38]. Screening of cyanobacteria leads to the discovery of three analogs of scytophycins, including 6-hydroxyscytophycin B (35), 19-O-demethylscytophycin C (36) and 6-hydroxy-7-O-methylscytophycin E (37) (Figure 7). These compounds (35–37) show strong inhibitory effect on the growth of KB (MIC values ranging from 1 to 5 ng/mL) and LoVo cells (MIC values ranging from 10 to 50 ng/mL) [23]. The cytotoxic tolytoxin (38) was isolated from terrestrial cyanobacterium Tolypothrix conglutinata, collected from Fanning Island [39], and displays excellent cytotoxicity against LoVo and KB cells with IC50 values of 8.4 and 5.3 nM, respectively [24].
Debromoaplysiatoxin (39) was isolated from the marine cyanobacterium Lyngbya majuscula, collected from Hawaii [40], and shows potent cytotoxicity against mouse lymphocytic leukemia P-388 [25]. Four analogs of debromoaplysiatoxin (39), including oscillatoxin A (40), 19,21-dibromooscillatoxin A (41), 19-bromoaplysiatoxin (42) and 21-bromooscillatoxin A (43), were isolated from a mixture of marine cyanobacteria Oscillatoria nigroviridis and Schizothrix calcicola from Enewetak Island (Figure 8). These compounds (41–43) contain the same 14-membered macrocycle as debromoaplysiatoxin (39), but they are bromine-containing macrolides [41]. A 14-membered glycosidic macrolide, lyngbouilloside (44), was isolated from the marine cyanobacterium Lyngbya bouillonii, harvested from Papua New Guinea. It displays a modest cytotoxicity against neuroblastoma cells with an IC50 value of 17 µM [26]. Another 14-membered macrolide, koshikalide (45), was isolated from the marine cyanobacterium Lyngbya sp., collected from Mie Prefecture, Japan, and shows slight cytotoxicity against HeLa S3 cells with an IC50 value of 42 µg/mL [27]. In addition, the total synthesis of koshikalide (45) has been achieved by exploiting a novel convergent strategy [42]. A 14-membered marine macrolide, sanctolide A (46), containing a rare N-methyl enamide and a 2-hydroxyisovaleric acid, was obtained from the culture of cyanobacterium Oscillatoria sancta. It is cytotoxic against HT-29 and MDA-MB-435 cell lines [28], and its total synthesis was achieved [43].
Two cytotoxic marcolides, acutiphycin (47) and 20,21-didehydroacutiphycin (48), were isolated from freshwater cyanobacterium Oscillatoria acutissima, collected from Manoa Valley, Oahu, and possess strong cytotoxicity against KB and NIH/3T3 cells (ED50 < 1 μg/mL), as well as Lewis lung carcinoma [29]. A rare marine toxin, polycavernoside D (49), was obtained from the marine Okeania sp. collected from the Caribbean (Figure 9). The discovery of polycavernoside D, for the first time, provides a conclusive proof that these lethal toxins (polycavernosides) have, in fact, a cyanobacterial origin rather than other marine organisms. Polycavernoside D (49) displays cytotoxicity against the H-460 human lung cancer cell line in a dose-dependent manner, with an EC50 value of 2.5 µM [30]. Bastimolide A (50), isolated from the marine Okeania hirsuta from Bastimentos Park, Panama, is a rare 40-membered polyhydroxy macrolide consisting of one 1,3-diol, one 1,3,5-triol, six 1,5-diols and one tert-butyl group. Bastimolide A (50) exhibits strong cytotoxicity against Vero cells with an IC50 value of 2.1 µM [31].
A rare 40-membered macrolactone, nuiapolide (51), was isolated from Niihau marine cyanobacterium. As a polyhydroxylated macrolide, nuiapolide (51) contains a rare tert-butyl carbinol residue, and it displays anti-chemotactic activity against Jurkat cells and cancerous T lymphocytes and can trigger a predominant G2/M phase shift in the cell cycle [32].

3. Antibacterial Activity

Some macrolides, such as erythromycin and azithromycin, have shown excellent antibacterial activity and are widely used in clinical practice of various types of bacterial infections [44]. Some macrolides from cyanobacteria also show good antibacterial activities. Cyanobacterium-derived macrolides with antimicrobial properties are listed in Table 2.
Scytophycins C–E (32–34) were isolated from the terrestrial cyanobacterium Scytonema pseudohofmanni, collected from Oahu, Hawaii, and were shown to exhibit weak antibacterial activity [37]. Three analogs of scytophycin C (32), including 6-hydroxyscytophycin B (35), 19-O-demethylscytophycin C (36) and 6-hydroxy-7-O-methylsctophycin E (37), were isolated from the cyanobacteria S. mirabile, S. burmanicurn and S. ocellatum, respectively. These macrolides (35–37) display antifungal activity against Aspergillus oryzae, Candida albicans, Penicillium notatum and Saccharomyces cerevisiae [23]. The cytotoxin, tolytoxin (38), was isolated from the terrestrial cyanobacterium Tolypothrix conglutinata, collected from Fanning Island [39], and was found to exhibit potent antifungal activity against various yeasts and filamentous fungi (MICs of 0.25–8 nM) [24].
A bioactive marcolide, 7-OMe-scytophycin B (52), was identified from a culture of a marine cyanobacterium and was found to exhibit antifungal activity against Candida albicans HAMbI 484 and Candida guilliermondii HAMBI 257 with MIC values of 0.40 and 0.80 mM and IC50 values of 0.19 and 0.23 mM, respectively [45]. Two 40-membered macrolactones, amantelides A,B (53,54), are composed of a 1,3-diol and contiguous 1,5-diol units and a tert-butyl substituent. These compounds were isolated from a Guam cyanobacterium belonging to the family Oscillatoriales (Figure 10). Amantelide A (53) shows a broad spectrum of inhibitory effects on the growth of both eukaryotic and prokaryotic cells. The growth of the fungi Lindra thalassiae and Fusarium sp. is completely inhibited when the concentration of amantelide A (53) is 62.5 μg/mL. When the concentration of amantelide B (54) is 6.25 μg/mL, the growth of the fungus Dendryphiella salina is completely inhibited [46].

4. Effects of Cyanobacterium-Derived Macrolides on Animals

Toxin-producing cyanobacterial blooms are a potential health risk for other living organisms, including humans [47]. Cyanobacterium-derived macrolides show toxicity to animals, such as brine shrimp and mice. The effects of cyanobacterium-derived macrolides on fauna are described in Table 3.
The cytotoxic macrolactone, lyngbyabellin A (1), exhibits potent toxicity to mice in vivo trials (lethal dose of 2.4 to 8.0 mg/kg; sublethal dose of 1.2 to 1.5 mg/kg) [6]. Tolytoxin (38) is highly toxic to mice with a sublethal dose (ip) of 1.5 mg /kg [24].
A 14-membered macrolide, sanctolide A (48), shows high toxicity toward the brine shrimp with an LC50 value of 23.5 μM [28]. A 10-membered ring macrolide, gloeolactone (55), was isolated from the cyanobacterium Gloeotrichia sp., harvested in Clark Canyon Reservoir (Figure 11). Gloeolactone (55) exhibits weak toxicity to brine shrimp. All brine shrimps are dead when the concentration of gloeolactone (55) is 125 μg/mL [48]. Phormidolide (56) was isolated from the marine cyanobacterium Phormidium sp. cultured in Indonesia and was found to exhibit very high toxicity (LC50 value of 1.5 μM) in the brine shrimp test [49].
A symmetrical macrolide dimer, cyanolide A (57), was obtained from the marine cyanobacterium Lyngbya bouillonii collected from Papua New Guinea. Cyanolide A (57) displays potent molluscicidal activity against the snail vector Biomphalaria glabrata with an LC50 value of 1.2 µM. Cyanolide A (57) can be used as a new, potent molluscicidal agent to effectively control the spread of schistosomiasis [50]. Its total synthesis has been accomplished [51].

5. Other Bioactivity

Cyanobacterium-derived macrolides with rich chemical diversity show various important bioactivities (Table 4). The macrolide biselyngbyaside (17), isolated from the marine cyanobacterium Lyngbya sp., has been investigated for its effects on osteoclast differentiation and function. Biselyngbyaside (17) inhibits RANKL-induced osteoclastogenesis by inhibiting the expression of c-Fos and NFATc1 in mouse monocytic RAW264 cells. Therefore, biselyngbyaside (17) is a potentially promising compound with therapeutic and preventive activities against bone-lytic diseases [52]. A toxic cyanobacterial macrolide, debromoaplysiatoxin (39), has been found to cause severe cutaneous inflammation in humans and other animals after topical application [25].
A rare 40-membered polyhydroxy macrolide, bastimolide A (50), exhibits high selectivity and antimalarial activity against four drug-resistant malaria parasite strains, including TM90-C2A, TM90-C2B, W2 and TM91-C235, with IC50 values of 80, 90, 140 and 270 nM, respectively. It has been proven that bastimolide A (50) is a potentially promising antimalarial lead compound with high selectivity and antimalarial activity against drug-resistant strains [31]. Malyngolide dimer (58) was isolated from the marine cyanobacterium Lyngbya majuscula collected from Panama and was shown to exhibit moderate antimalarial activity against chloroquine-resistant Plasmodium falciparum (W2) with an IC50 value of 19 µM [53].
A novel SIRT2-selective inhibitor, tanikolide dimer (59), was isolated from marine cyanobacterium Lyngbya majuscula collected from Madagascar, and it possesses a symmetrical dimer, which has been elucidated by comparison of the natural and synthetic stereoisomers using chiral GC-MS (Figure 12). The tanikolide dimer (59) is a potent and selective SIRT2 inhibitor with an IC50 value of 176 nM [54].
An unusually stabilized neuroactive macrolide, palmyrolide A(60), was isolated, via an assay-based screening program for new neuroactive compounds from cyanobacteria Leptolyngbya cf. and Oscillatoria spp. harvested in Palmyra Atoll. Palmyrolide A (60) contains a rare N-methyl enamide and an intriguing tert-butyl group, and it can potently inhibit Ca2+ oscillations in murine cerebrocortical neuronal cells with an IC50 value of 3.70 µM. Moreover, palmyrolide A (60) can significantly block the sodium channel activity of neuro-2a cells (IC50 value of 5.2 µM) without appreciable cytotoxicity. The above intriguing experimental results suggest that palmyrolide A (60) could be a promising drug candidate for further pharmacological exploration [55], and its total synthesis has been completed [56].
A dimeric macrolide, cocosolide (61), was isolated from the marine cyanobacterium Symploca sp. from Guam, and it strongly inhibits IL-2 production in both T-cell receptor-dependent and independent manners. Both the presence of the sugar moiety and the integrity of the dimeric structure ensure the functionality of cocosolide (61). In addition, the total synthesis of cocosolide (61) has been accomplished [7].
Three novel nitrogen-containing macrolides, laingolide (62) [57], laingolide A (63) and madangolide (64) [58], have been identified from the marine cyanobacterium Lyngbya bouillonii harvested in Laing Island, Papua-New Guinea (Figure 12). The structures of these macrolides (62–64) contain a lactone ring of 15, 15 and 17 members, respectively [58].

6. Conclusions

Cyanobacteria are rich sources of various natural products with unprecedented pharmacological and biological activities. Up to the end of 2016, a total of 64 macrolide compounds have been isolated from cyanobacteria, including 49 macrolides from marine cyanobacteria and 15 macrolides from terrestrial cyanobacteria. More than half of the cyanobacterium-derived macrolides, a total of 36 compounds, were isolated from the cyanobacterial genus Lyngbya species, particularly from Lyngbya majuscula. Most of these cyanobacterium-derived macrolides possess several noticeable bioactivities, including antitumor, antibacterial and antimalarial. The overwhelming majority of cyanobacteria derived macrolides (1–51) display in vitro antitumor activity. Secondary metabolites of cyanobacteria are widely evaluated for their antitumor effects since many metabolites of cyanobacteria have exhibited potent antitumor activities. Some of these macrolides, including tolytoxin (38), bastimolide A (50) and tanikolide dimer (59), exhibited surprisingly strong bioactivity, thus representing potential new drug lead compounds, which are worthy of further research on synthesis and pharmacological activity. The total synthesis of 10 bioactive macrolides, such as cocosolide, has been achieved with a great deal of efforts. The research on the total synthesis of macrolides will promote pharmacologic research and create new opportunities to undertake research in drug discovery, medicine design and large-scale manufacturing. At present, three scholars, including Luesch, Moore and Gerwick, have greatly contributed to the discovery of new macrolides from cyanobacteria. Cyanobacteria have great potentials as sustainable sources for the production of bioactive metabolites because of their rapid growth, genetic tractability and cultivable property. Although cyanobacteria possess the cultivable properties similar to those of microorganisms, cyanobacteria have attracted far less attention than microorganisms. More efforts should be devoted to improving the production of bioactive metabolites in cyanobacteria via cultivation design, metabolic engineering together with efficient isolation. In addition, the programs for drug discovery from cyanobacteria, including the Panama International Cooperative Biodiversity Group (ICGB) program, might facilitate and enhance drug discovery from cyanobacteria. A systematic review on macrolides from cyanobacteria would help establish an effective support system for the discovery and development of cyanobacterium-derived macrolides, and such a support system could also facilitate collection, purification and identification of bioactive macrolides, leading to improve bioactivity assay, synthesis, data analysis and information technology.

Acknowledgments

This work was financially supported by the National Natural Science Foundation of China (41406163), the 863 Program of China (2013AA092902), the Ningbo Marine Algae Biotechnology Team (2011B81007), the Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund, the National 111 Project of China, the Scientific Research Foundation for Returned Scholars of ZJHRSS and the K.C. Wong Magna Fund in Ningbo University.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Capper, A.; Erickson, A.A.; Ritson-Williams, R.; Becerro, M.A.; Arthur, K.A.; Paul, V.J. Palatability and chemical defences of benthic cyanobacteria to a suite of herbivores. J. Exp. Mar. Biol. Ecol. 2016, 474, 100–108. [Google Scholar] [CrossRef]
  2. Tan, L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 2007, 68, 954–979. [Google Scholar] [CrossRef] [PubMed]
  3. Napolitano, J.G.; Daranas, A.H.; Norte, M.; Fernández, J.J. Marine macrolides, a promising source of antitumor compounds. Anti-Cancer Agent Med. Chem. 2009, 9, 122–137. [Google Scholar] [CrossRef]
  4. Kollár, P.; Rajchard, J.; Balounová, Z.; Pazourek, J. Marine natural products: bryostatins in preclinical and clinical studies. Pharm. Biol. 2014, 52, 237–242. [Google Scholar] [CrossRef] [PubMed]
  5. Belakhov, V.V.; Garabadzhiu, A.V. Polyene macrolide antibiotics: mechanisms of inactivation, ways of stabilization, and methods of disposal of unusable drugs (review). Russ. J. Gen. Chem. 2015, 85, 2985–3001. [Google Scholar] [CrossRef]
  6. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J.; Mooberry, S.L. Isolation, structure determination, and biological activity of lyngbyabellin A from the marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2000, 63, 611–615. [Google Scholar] [CrossRef] [PubMed]
  7. Gunasekera, S.P.; Li, Y.; Ratnayake, R.; Luo, D.M.; Lo, J.; Reibenspies, J.H.; Xu, Z.S.; Clare-Salzler, M.J.; Ye, T.; Paul, V.J.; Luesch, H. Discovery, total synthesis and key structural elements for the immunosuppressive activity of cocosolide, a symmetrical glycosylated macrolide dimer from marine cyanobacteria. Chem. Eur. J. 2016, 22, 8158–8166. [Google Scholar] [CrossRef] [PubMed]
  8. Klein, D.; Braekman, J.C.; Daloze, D.; Hoffmann, L.; Demoulin, V. Lyngbyaloside, a novel 2,3,4-Tri-O-methyl-6-deoxy-r-mannopyranoside macrolide from Lyngbya bouillonii (Cyanobacteria). J. Nat. Prod. 1997, 60, 1057–1059. [Google Scholar] [CrossRef]
  9. DeVita, V.T.J.; Rosenberg, S.A. Two hundred years of cancer research. N. Engl. J. Med. 2012, 366, 2207–2214. [Google Scholar] [CrossRef] [PubMed]
  10. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. Isolation and structure of the cytotoxin lyngbyabellin B and absolute configuration of lyngbyapeptin A from the marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2000, 63, 1437–1439. [Google Scholar] [CrossRef] [PubMed]
  11. Han, B.N.; McPhail, K.L.; Gross, H.; Goeger, D.E.; Mooberry, S.L.; Gerwick, W.H. Isolation and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula. Tetrahedron 2005, 61, 11723–11729. [Google Scholar] [CrossRef]
  12. Choi, H.; Mevers, E.; Byrum, T.; Valeriote, F.A.; Gerwick, W.H. Lyngbyabellins K–N from Two Palmyra Atoll Collections of the marine cyanobacterium Moorea bouillonii. Eur. J. Org. Chem. 2012, 5141–5150. [Google Scholar] [CrossRef] [PubMed]
  13. Luesch, H.; Yoshida, W.Y.; Harrigan, G.G.; Doom, J.P.; Moore, R.E.; Paul, V.J. Lyngbyaloside B, a new glycoside macrolide from a palauan marine cyanobacterium, Lyngbya sp. J. Nat. Prod. 2002, 65, 1945–1948. [Google Scholar] [CrossRef] [PubMed]
  14. Matthew, S.; Salvador, L.A.; Schupp, P.J.; Paul, V.J.; Luesch, H. Cytotoxic halogenated macrolides and modified peptides from the apratoxin-producing marine cyanobacterium Lyngbya bouillonii from Guam. J. Nat. Prod. 2010, 73, 1544–1552. [Google Scholar] [CrossRef] [PubMed]
  15. Teruya, T.; Sasaki, H.; Kitamura, K.; Nakayama, T.; Suenaga, K. Biselyngbyaside, a macrolide glycoside from marine cyanobacterium Lyngbya sp. Org. Lett. 2009, 11, 2421–2424. [Google Scholar] [CrossRef] [PubMed]
  16. Morita, M.; Ohno, O.; Teruya, T.; Yamori, T.; Inuzuka, T.; Suenaga, K. Isolation and structures of biselyngbyasides B, C, and D from the marine cyanobacterium Lyngbya sp., and the biological activities of biselyngbyasides. Tetrahedron 2012, 68, 5984–5990. [Google Scholar] [CrossRef]
  17. Watanabe, A.; Ohno, O.; Morita, M.; Inuzuka, T.; Suenaga, K. Structures and biological activities of novel biselyngbyaside analogs isolated from the marine cyanobacterium Lyngbya sp. Bull. Chem. Soc. Jpn. 2015, 88, 1256–1264. [Google Scholar] [CrossRef]
  18. Morita, M.; Ohno, O.; Suenaga, K. Biselyngbyolide A, a novel cytotoxic macrolide from the marine cyanobacterium Lyngbya sp. Chem. Lett. 2012, 41, 165–167. [Google Scholar] [CrossRef]
  19. Ohno, O.; Watanabe, A.; Morita, M.; Suenaga, K. Biselyngbyolide B, a novel ER stress-inducer isolated from the marine cyanobacterium Lyngbya sp. Chem. Lett. 2014, 43, 287–289. [Google Scholar] [CrossRef]
  20. MacMillan, J.B.; Molinski, T.F. Caylobolide A, a unique 36-membered macrolactone from a Bahamian Lyngbya majuscula. Org. Lett. 2002, 4, 1535–1538. [Google Scholar] [CrossRef] [PubMed]
  21. Salvador, L.A.; Paul, V.J.; Luesch, H. Caylobolide B, a macrolactone from symplostatin 1-producing marine cyanobacteria phormidium spp. from Florida. J. Nat. Prod. 2010, 73, 1606–1609. [Google Scholar] [CrossRef] [PubMed]
  22. Andrianasolo, E.H.; Gross, H.; Goeger, D.; Musafija-Girt, M.; McPhail, K.; Leal, R.M.; Mooberry, S.L.; Gerwick, W.H. Isolation of swinholide A and related glycosylated derivatives from two field collections of marine cyanobacteria. Org. Lett. 2005, 7, 1375–1378. [Google Scholar] [CrossRef] [PubMed]
  23. Carmeli, S.; Moore, R.E.; Patterson, G.M.L. Tolytoxin and new scytophycins from three species of Scytonema. J. Nat. Prod. 1990, 53, 1533–1542. [Google Scholar] [CrossRef] [PubMed]
  24. Patterson, G.M.L.; Carmeli, S. Biological effects of tolytoxin (6-hydroxy-7-O-methyl-scytophycin b), a potent bioactive metabolite from cyanobacteria. Arch. Microbiol. 1992, 157, 406–410. [Google Scholar] [CrossRef] [PubMed]
  25. Mynderse, J.S.; Moore, R.E.; Kashiwagi, M.; Norton, T.R. Antileukemia activity in the Osciliatoriaceae: Isolation of debromoaplysiatoxin from Lyngbya. Science 1977, 196, 538–540. [Google Scholar] [CrossRef] [PubMed]
  26. Tan, L.T.; Márquez, B.L.; Gerwick, W.H. Lyngbouilloside, a novel glycosidic macrolide from the marine cyanobacterium Lyngbya bouillonii. J. Nat. Prod. 2002, 65, 925–928. [Google Scholar] [CrossRef] [PubMed]
  27. Iwasaki, A.; Teruya, T.; Suenaga, K. Isolation and structure of koshikalide, a 14-membered macrolide from the marine cyanobacterium Lyngbya sp. Tetrahedron Lett. 2010, 51, 959–960. [Google Scholar] [CrossRef]
  28. Kang, H.S.; Krunic, A.; Orjala, J. Sanctolide A, a 14-membered PK-NRP hybrid macrolide from the cultured cyanobacterium Oscillatoria sancta (SAG 74.79). Tetrahedron Lett. 2012, 53, 3563–3567. [Google Scholar] [CrossRef] [PubMed]
  29. Barchi, J.J.; Moore, R.E.; Patterson, G.M.L. Acutiphycin and 20,21-didehydroacutiphycin, new antineoplastic agents from the cyanophyte Oscillatoria acutissima. J. Am. Chem. Soc. 1984, 106, 8193–8197. [Google Scholar] [CrossRef]
  30. Navarro, G.; Cummings, S.; Lee, J.; Moss, N.; Glukhov, E.; Valeriote, F.A.; Gerwick, L.; Gerwick, W.H. Isolation of polycavernoside D from a marine cyanobacterium. Environ. Sci. Technol. Lett. 2015, 2, 166–170. [Google Scholar] [CrossRef]
  31. Shao, C.L.; Linington, R.G.; Balunas, M.J.; Centeno, A.; Boudreau, P.; Zhang, C.; Engene, N.; Spadafora, C.; Mutka, T.S.; Kyle, D.E.; Gerwick, L.; Wang, C.Y.; Gerwick, W.H. Bastimolide A, a potent antimalarial polyhydroxy macrolide from the marine cyanobacterium Okeania hirsute. J. Org. Chem. 2015, 80, 7849–7855. [Google Scholar] [CrossRef] [PubMed]
  32. Mori, S.; Williams, H.; Cagle, D.; Karanovich, K.F.; Horgen, D.; Smith, R.; Watanabe, C.M.H. Macrolactone nuiapolide, isolated from a Hawaiian marine cyanobacterium, exhibits anti-chemotactic activity. Mar. Drugs 2015, 13, 6274–6290. [Google Scholar] [CrossRef] [PubMed]
  33. Fuwa, H.; Yamagata, N.Y.; Okuaki, Y.T.; Ogata, Y.Y.; Saito, A.; Sasaki, M. total synthesis and complete stereostructure of a marine macrolide glycoside, (-)-lyngbyaloside B. Chem. Eur. J. 2016, 22, 6815–6829. [Google Scholar] [CrossRef] [PubMed]
  34. Chang, C.; Stefan, E.; Taylo, R.E. Total synthesis and structural reassignment of lyngbyaloside C highlighted by intermolecular ketene esterification. Chem. Eur. J. 2015, 21, 10681–10686. [Google Scholar] [CrossRef] [PubMed]
  35. Chandrasekhar, S.; Rajesh, G.; Naresh, T. Enantioselective synthesis of the C5–C23 segment of biselyngbyaside. Tetrahedron Lett. 2013, 54, 252–255. [Google Scholar] [CrossRef]
  36. Yadav, J.S.; Swapnil, N.; Venkatesh, M.; Prasad, A.R. Studies directed toward the synthesis of caylobolide A: convergent synthesis of C21–C40 subunit. Tetrahedron Lett. 2014, 55, 1164–1167. [Google Scholar] [CrossRef]
  37. Ishibashi, M.; Moore, R.E.; Patterson, G.M.L. Scytophycins, cytotoxic and antimycotic agents from the cyanophyte Scytonema pseudohofmanni. J. Org. Chem. 1986, 51, 5300–5306. [Google Scholar] [CrossRef]
  38. Cui, J.; Watanabe, T.; Shibasaki, M. Catalytic asymmetric synthesis of key intermediate for scytophycin C. Tetrahedron Lett. 2016, 57, 446–448. [Google Scholar] [CrossRef]
  39. Moore, R.E. Constituents of blue-green algae. In Marine Natural Products; Scheuer, P.J., Ed.; Academic Press: New York, NY, USA, 1981; Volume 4, pp. 1–52. [Google Scholar]
  40. Solomon, A.E.; Stoughton, R.B. Dermatitis from purified sea algae toxin (debromoaplysiatoxin). Arch. Dermatol. 1978, 114, 1333–1335. [Google Scholar] [CrossRef] [PubMed]
  41. Mynderse, J.S.; Moore, R.E. Toxins from Blue-Green algae: Structures ofoscillatoxin A and three related bromine-containing toxins. J. Org. Chem. 1978, 43, 2301–2303. [Google Scholar] [CrossRef]
  42. Kunifuda, K.; Iwasaki, A.; Nagamoto, M.; Suenaga, K. Total synthesis and absolute configuration of koshikalide. Tetrahedron Lett. 2016, 57, 3121–3123. [Google Scholar] [CrossRef]
  43. Yadav, J.S.; Suresh, B.; Srihari, P. Stereoselective total synthesis of the marine macrolide sanctolide A. Eur. J. Org. Chem. 2015, 5856–5863. [Google Scholar] [CrossRef]
  44. Frayman, K.; Robinson, P. Macrolide therapy in cystic fibrosis: New developments in clinical use. Clin. Investig. 2013, 3, 1179–1186. [Google Scholar] [CrossRef]
  45. Shishido, T.K.; Humisto, A.; Jokela, J.; Liu, L.W.; Wahlsten, M.; Tamrakar, A.; Fewer, D.P.; Permi, P.; Andreote, A.P.D.; Fiore, M.F.; Sivonen, K. Antifungal compounds from cyanobacteria. Mar. Drugs 2015, 13, 2124–2140. [Google Scholar] [CrossRef] [PubMed]
  46. Salvador-Reyes, L.A.; Sneed, J.; Paul, V.J.; Luesch, H. Amantelides A and B, polyhydroxylated macrolides with differential broad-spectrum cytotoxicity from a guamanian marine cyanobacterium. J. Nat. Prod. 2015, 78, 1957–1962. [Google Scholar] [CrossRef] [PubMed]
  47. Wood, R. Acute animal and human poisonings from cyanotoxin exposure—A review of the literature. Environ. Int. 2016, 9, 276–282. [Google Scholar] [CrossRef] [PubMed]
  48. Stierle, D.B.; Stierle, A.A.; Bugni, T.; Loewen, G. Gloeolactone, a new epoxy lactone from a blue-green alga. J. Nat. Prod. 1998, 61, 251–252. [Google Scholar] [CrossRef] [PubMed]
  49. Williamson, R.T.; Boulanger, A.; Vulpanovici, A.; Roberts, M.A.; Gerwick, W.H. Structure and absolute stereochemistry of phormidolide, a new toxic metabolite from the marine cyanobacterium phormidium sp. J. Org. Chem. 2002, 67, 7927–7936. [Google Scholar] [CrossRef] [PubMed]
  50. Pereira, A.R.; McCue, C.F.; Gerwick, W.H. Cyanolide A, a glycosidic macrolide with potent molluscicidal activity from the Papua New Guinea cyanobacterium Lyngbya bouillonii. J. Nat. Prod. 2010, 73, 217–220. [Google Scholar] [CrossRef] [PubMed]
  51. Bates, R.W.; Lek, T.G. A synthesis of cyanolide A by intramolecular oxa-michael addition. Synthesis 2014, 46, 1731–1738. [Google Scholar] [CrossRef]
  52. Yonezawa, T.; Mase, N.; Sasaki, H.; Teruya, T.; Hasegawa, S.; Cha, B.Y.; Yagasaki, K.; Suenaga, K.; Nagai, K.; Woo, J.T. Biselyngbyaside, isolated from marine cyanobacteria, inhibits osteoclastogenesis and induces apoptosis in mature osteoclasts. J. Cell. Biochem. 2012, 113, 440–448. [Google Scholar] [CrossRef] [PubMed]
  53. Gutiérrez, M.; Tidgewell, K.; Capson, T.L.; Engene, N.; Almanza, A.; Schemies, J.; Jung, M.; Gerwick, W.H. Malyngolide Dimer, a bioactive symmetric cyclodepside from the panamanian marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2010, 73, 709–711. [Google Scholar] [CrossRef] [PubMed]
  54. Gutierrez, M.; Andrianasolo, E.H.; Shin, W.K.; Goeger, D.E.; Yokochi, A.; Schemies, J.; Jung, M.; France, D.; Cornell-Kennon, S.; Lee, E. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolideseco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J. Org. Chem. 2009, 74, 5267–5275. [Google Scholar] [CrossRef] [PubMed]
  55. Pereira, A.R.; Cao, Z.Y.; Engene, N.; Soria-Mercado, I.E.; Murray, T.F.; Gerwick, W.H. Palmyrolide A, an Unusually Stabilized Neuroactive Macrolide from Palmyra Atoll Cyanobacteria. Org. Lett. 2010, 12, 4490–4493. [Google Scholar] [CrossRef] [PubMed]
  56. Sudhakar, G.; Reddy, K.J.; Nanubolu, J.B. Total synthesis of palmyrolide A and its 5,7-epi isomers. Org. Lett. 2010, 12, 4490–4493. [Google Scholar] [CrossRef]
  57. Klein, D.; Braekman, J.C.; Daloze, D. Laingolide, a novel 15-membered macrolide from Lyngbya bouillonii (cyanophyceae). Tetrahedron Lett. 1996, 37, 7519–7520. [Google Scholar] [CrossRef]
  58. Klein, D.; Braekman, J.C.; Daloze, D.; Hoffmann, L.; Castillo, G.; Demoulin, V. Madangolide and laingolide A, two novel macrolides from Lyngbya bouillonii (Cyanobacteria). J. Nat. Prod. 1999, 62, 934–936. [Google Scholar] [CrossRef] [PubMed]
Marinedrugs 15 00126 g001 550
Figure 1. Anti-neoplastic profiling results for cyanobacterium-derived macrolides on different cell lines. Data are represented as IC50 [log(μM)].
Figure 1. Anti-neoplastic profiling results for cyanobacterium-derived macrolides on different cell lines. Data are represented as IC50 [log(μM)].
Marinedrugs 15 00126 g001
Marinedrugs 15 00126 g002a 550Marinedrugs 15 00126 g002b 550
Figure 2. Chemical structures of Compounds 1–11.
Figure 2. Chemical structures of Compounds 1–11.
Marinedrugs 15 00126 g002aMarinedrugs 15 00126 g002b
Marinedrugs 15 00126 g003 550
Figure 3. Chemical structures of Compounds 12–16.
Figure 3. Chemical structures of Compounds 12–16.
Marinedrugs 15 00126 g003
Marinedrugs 15 00126 g004 550
Figure 4. Chemical structures of Compounds 17–24.
Figure 4. Chemical structures of Compounds 17–24.
Marinedrugs 15 00126 g004
Marinedrugs 15 00126 g005 550
Figure 5. Chemical structures of Compounds 25 and 26.
Figure 5. Chemical structures of Compounds 25 and 26.
Marinedrugs 15 00126 g005
Marinedrugs 15 00126 g006 550
Figure 6. Chemical structures of Compounds 27–29.
Figure 6. Chemical structures of Compounds 27–29.
Marinedrugs 15 00126 g006
Marinedrugs 15 00126 g007a 550Marinedrugs 15 00126 g007b 550
Figure 7. Chemical structures of Compounds 30–38.
Figure 7. Chemical structures of Compounds 30–38.
Marinedrugs 15 00126 g007aMarinedrugs 15 00126 g007b
Marinedrugs 15 00126 g008a 550Marinedrugs 15 00126 g008b 550
Figure 8. Chemical structures of Compounds 39–46.
Figure 8. Chemical structures of Compounds 39–46.
Marinedrugs 15 00126 g008aMarinedrugs 15 00126 g008b
Marinedrugs 15 00126 g009a 550Marinedrugs 15 00126 g009b 550
Figure 9. Chemical structures of Compounds 47–51.
Figure 9. Chemical structures of Compounds 47–51.
Marinedrugs 15 00126 g009aMarinedrugs 15 00126 g009b
Marinedrugs 15 00126 g010a 550Marinedrugs 15 00126 g010b 550
Figure 10. Chemical structures of Compounds 52–54.
Figure 10. Chemical structures of Compounds 52–54.
Marinedrugs 15 00126 g010aMarinedrugs 15 00126 g010b
Marinedrugs 15 00126 g011 550
Figure 11. Chemical structures of Compounds 55–57.
Figure 11. Chemical structures of Compounds 55–57.
Marinedrugs 15 00126 g011
Marinedrugs 15 00126 g012 550
Figure 12. Chemical structures of Compounds 58–64.
Figure 12. Chemical structures of Compounds 58–64.
Marinedrugs 15 00126 g012
Table
Table 1. Anti-neoplastic property of cyanobacterium-derived macrolides on different cell lines.
Table 1. Anti-neoplastic property of cyanobacterium-derived macrolides on different cell lines.
MetaboliteSourceLocationTarget Cell LinesConcentration/EffectReference
lyngbyabellin A (1)Lyngbya majusculaGuamKB cells and LoVo cellsIC50 value of 0.03 and 0.50 µg/mL respectively[6]
lyngbyabellin B (2)Lyngbya majusculaGuamKB cells and LoVo cellsIC50 value of 0.10 and 0.83 µg/mL respectively[10]
lyngbyabellin E (3)Lyngbya majusculaPapua New GuineaNCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cellsLC50 value of 0.4 and 1.2 µM respectively[11]
lyngbyabellin F (4)Lyngbya majusculaPapua New GuineaNCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cellsLC50 value of 1.0 and 1.8 µM respectively[11]
lyngbyabellin G (5)Lyngbya majusculaPapua New GuineaNCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cellsLC50 value of 2.2 and 4.8 µM respectively[11]
lyngbyabellin H (6)Lyngbya majusculaPapua New GuineaNCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cellsLC50 value of 0.2 and 1.4 µM respectively[11]
lyngbyabellin I (7)Lyngbya majusculaPapua New GuineaNCI-H460 human lung tumor and neuro-2a mouse neuroblastoma cellsLC50 value of 1.0 and 0.7 µM respectively[11]
lyngbyabellin N (10)Moorea bouilloniiPalmyra Atoll, USAH-460 human lung carcinoma and HCT116 colon cancer cell linesIC50 value of 0.0048–1.8 µM and 15 µM respectively[12]
lyngbyaloside B (13)Lyngbya sp.PalauKB cells and LoVo cellsIC50 value of 4.3 and 15 µM respectively[13]
2-epi-lyngbyalosid (14)Lyngbya bouilloniiApra Harbor, GuamHT29 colorectal adenocarcinoma and HeLa cellsIC50 value of 38 and 33 µM respectively[14]
18E-lyngbyaloside C (15)Lyngbya bouilloniiApra Harbor, GuamHT29 colorectal adenocarcinoma and HeLa cellsIC50 value of 13 and 9.3 µM respectively[14]
18Z-lyngbyaloside C (16)Lyngbya bouilloniiApra Harbor, GuamHT29 colorectal adenocarcinoma and HeLa cellsIC50 value of >100 µM and 53 µM respectively[14]
biselyngbyaside (17)Lyngbya sp.Tokunoshima Island, JapanHeLa S3 cellsIC50 value of 0.1 μg/mL [15]
biselyngbyaside B (18)Lyngbya sp.Tokunoshima Island, JapanHeLa S3 cells and HL60 cellsIC50 value of 3.5 and 0.82 µM respectively[16]
biselyngbyaside E (21)Lyngbya sp.Ishigaki Island, JapanHeLa and HL60 cells IC50 value of 0.19 and 0.071 µM respectively[17]
biselyngbyaside F (22)Lyngbya sp. Ishigaki Island, JapanHeLa and HL60 cells IC50 value of 3.1 and 0.66 µM respectively[17]
biselyngbyolide A (23)Lyngbya sp.Tokunoshima Island, JapanHeLa S3 cells and HL60 cellsIC50 value of 0.22 and 0.027 µM respectively[18]
biselyngbyolide B (24)Lyngbya sp.Ishigaki Island, JapanHeLa S3 cells and HL60 cellsIC50 value of 0.028 and 0.0027 µM respectively[19]
caylobolide A (25)Lyngbya majusculaBahamian human colon tumor cells HCT 116IC50 values of 9.9 µM[20]
caylobolide B (26)Phormidium spp.Florida USAHT29 colorectal adenocarcinoma and HeLa cervical carcinoma cellsIC50 value of 4.5 and 12.2 µM respectively[21]
swinholide A (27)Symploca cf. sp.Fijiseveral cancer cell linesIC50 values of 0.37 nM–1.0 µM[22]
ankaraholide A (28)Geitlerinema sp.MadagascarNCI-H460, Neuro-2a cells and MDA-MB-435 cellsIC50 value of 119, 262 and 8.9 nM respectively[22]
scytophycin A (30)Scytonema pseudohofmanniOahu, Hawaiihuman carcinoma of nasopharynx Cell (KB cells)IC50 value of 1 ng/mL[23]
scytophycin B (31)Scytonema pseudohofmanniOahu, HawaiiKB cellsIC50 value of 1 ng/mL[23]
scytophycins C-E (32–34)Scytonema pseudohofmanniOahu, HawaiiKB cellsIC50 value of 10–100 ng/mL[23]
6-hydroxyscytophycin B (35)Scytonema mirabilecultured KB cells and LoVo cellsMICs of 1–5 and 10–50 ng/mL respectively[23]
19-O-demethylscytophycin C (36)Scytonema burmanicurncultured KB cells and LoVo cellsMICs of 1–5 and 10–50 ng/mL respectively[23]
6-hydroxy-7-O-methylscytophycin E (37)Scytonema ocellatumcultured KB cells and LoVo cellsMICs of 1–5 and 10–50 ng/mL respectively[23]
tolytoxin (38)Tolypothrix conglutinata var. colorataFanning IslandKB cells and LoVo cellsIC50 value of 8.4 and 5.3 nM respectively[24]
debromoaplysiatoxin (39)Lyngbya majusculaMarshall IslandsP-388 lymphocytic mouse leukemiaweak[25]
lyngbouilloside (44)Lyngbya bouilloniiPapua New Guineaneuroblastoma cells IC50 value of 17 µM[26]
koshikalide (45)Lyngbya sp.Mie PrefectureHeLa S3 cellsIC50 value of 42 µg/mL[27]
sanctolide A (46)Oscillatoria sanctaculturedHT-29 and MDA-MB-435 cell linesnd a[28]
acutiphycin (47)Oscillatoria acutissimaManoa Valley Oahu, HawaiiKB cells and NIH/3T3 cells ED50 < 1 µg/mL[29]
20,21-didehydroacutiphycin (48)Oscillatoria acutissimaManoa Valley Oahu, HawaiiKB cells and NIH/3T3 cells ED50 < 1 µg/mL[29]
polycavernoside D (49)Okeania sp.Puerto Rican H-460 human lung cancer cell linesEC50 value of 2.5 µM[30]
bastimolide A (50)Okeania hirsutaPanamaVero cells IC50 value of 2.1 µM[31]
nuiapolide (51)colonial cyanobacterium (071905-NII-01)HawaiiJurkat cells and cancerous T lymphocytesanti-chemotactic activity [32]
a Not determined.
Table
Table 2. Antibacterial and antifungal macrolides.
Table 2. Antibacterial and antifungal macrolides.
MetaboliteSourceLocationTargetConcentration/EffectReference
6-hydroxyscytophycin B (35)Scytonema mirabileculturedFungus (1) Aspergillus oryzae (2) Candida albicans (3) Penicillium notatum (4) Saccharomyces cerevisiaend a[23]
19-O-demethylscytophycin C (36)Scytonema burmanicurnculturedFungus (1) Aspergillus oryzae (2) Candida albicans (3) Penicillium notatum (4) Saccharomyces cerevisiaend a[23]
6-hydroxy-7-O-methylscytophycin E (37)Scytonema ocellatumculturedFungus (1) Aspergillus oryzae (2) Candida albicans (3) Penicillium notatum (4) Saccharomyces cerevisiaend a[23]
tolytoxin (38)Tolypothrix conglutinata var. colorataFanning IslandFungi Penicillium notatum and Rhizoctonia solani 1165MIC value of 0.25 nM respectively[24]
7-OMe-scytophycin B (52)Anabaena sp.culturedFungus Candida albicans HAMBI 484 and Candida guilliermondii HAMBI 257MIC values of 0.40 and 0.80 mM respectively; IC50 value of 0.19 and 0.23 µM respectively[45]
amantelide A (53)OscillatorialesGuamFungi Lindra thalassiae and Fusarium sp.totally inhibited of 62.5 μg/mL[46]
amantelide B (54)OscillatorialesGuamFungus Dendryphiella salinatotally inhibited of 6.25 μg/mL[46]
a Not determined.
Table
Table 3. Effects of cyanobacterium-derived macrolides on animals.
Table 3. Effects of cyanobacterium-derived macrolides on animals.
MetaboliteSourceLocationTarget FaunaImpactsReference
lyngbyabellin A (1)Lyngbya majusculaGuammiceLD50 value of 1.2–1.5 mg/kg[6]
tolytoxin (38)Scytonema pseudohofmanniculturedmiceLD50 value of 1.5 mg/kg[24]
sanctolide A (48)Oscillatoria sanctaculturedbrine shrimpLD50 value of 23.5 μM[28]
gloeolactone (55)Gloeotrichia sp.Clark Canyon Reservoirbrine shrimp100% killed at 125 µg/mL[48]
phormidolide (56)Phormidium sp.Sulawesi, Indonesiabrine shrimpLD50 value of 1.5 μM[49]
cyanolide A (57)Lyngbya bouilloniiPapua New Guineasnail vector Biomphalaria glabrataLD50 value of 1.2 μM[50]
Table
Table 4. Other bioactivity of cyanobacterium-derived macrolides.
Table 4. Other bioactivity of cyanobacterium-derived macrolides.
MetaboliteSourceLocationBiological ActivityReference
biselyngbyaside (17)Lyngbya sp.Okinawa Prefecture Japanosteoclast differentiation and function[52]
debromoaplysiatoxin (39)Lyngbya majusculaEnewetak Atoll, Marshall Islandsproduce an irritant pustular folliculitis in humans and cause a severe cutaneous inflammatory reaction in the rabbit and in hairless mice[25]
bastimolide A (50)Okeania hirsutaCaribbean coast of PanamaPlasmodium falciparum TM90-C2A, TM90-C2B, W2, TM91-C235 (IC50 values of 80, 90, 140 and 270 nM respectively)[31]
malyngolide dimer (58)Lyngbya majusculaPanamaPlasmodium falciparum (IC50 values of 19 µM)[53]
tanikolide dimer (59)Lyngbya majusculaMadagascarSIRT2 (IC50 = 176 nM to 2.4 µM)[54]
palmyrolide A (60)Leptolyngbya cf. Oscillatoria sp.Palmyra Atollsuppression of calcium influx in cerebrocortical neurons (IC50 value of 3.70 µM) sodium channel blocking activity in neuro-2a cells (IC50 value of 5.2 µM)[55]
cocosolide (61)Symploca sp.Guaminhibition of IL-2 production and T-cell proliferation[7]

Share and Cite

MDPI and ACS Style

Wang, M.; Zhang, J.; He, S.; Yan, X. A Review Study on Macrolides Isolated from Cyanobacteria. Mar. Drugs 2017, 15, 126. https://doi.org/10.3390/md15050126

AMA Style

Wang M, Zhang J, He S, Yan X. A Review Study on Macrolides Isolated from Cyanobacteria. Marine Drugs. 2017; 15(5):126. https://doi.org/10.3390/md15050126

Chicago/Turabian Style

Wang, Mengchuan, Jinrong Zhang, Shan He, and Xiaojun Yan. 2017. "A Review Study on Macrolides Isolated from Cyanobacteria" Marine Drugs 15, no. 5: 126. https://doi.org/10.3390/md15050126

APA Style

Wang, M., Zhang, J., He, S., & Yan, X. (2017). A Review Study on Macrolides Isolated from Cyanobacteria. Marine Drugs, 15(5), 126. https://doi.org/10.3390/md15050126

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop